J&J acquires lung cancer-focused robotics firm Auris Health in potential $5.75m deal
pharmafile | February 14, 2019 | News story | Manufacturing and Production, Research and Development, Sales and Marketing | Auris Health, Cancer, J&J, JJ, lung cancer, pharma, robotics
In a bid to bolster its footing in providing surgical treatments, Johnson & Johnson has announced it will acquire robotics specialist Auris Health via its subsidiary Ethicon in a deal worth potentially $5.75 million in cash.
This total value breaks down into an upfront cash payment of $3.4 billion and $2.35 billion in milestone payments. J&J will be looking to leverage Auris’ lung cancer-focused robotics expertise and an FDA-approved platform with bronchoscopic diagnostic and therapeutic applications which functions as a surgeon-controlled robot which can observe the inside of a patient’s body via cameras.
The deal has been made amidst predictions the healthcare robotics market could reach $12 billion by 2023.
“In this new era of health care, we’re aiming to simplify surgery, drive efficiency, reduce complications and improve outcomes for patients, ultimately making surgery safer,” commented Ashley McEvoy, Executive Vice President and Worldwide Chairman, Medical Devices at J&J. “We believe the combination of best-in-class robotics, advanced instrumentation and unparalleled end-to-end connectivity will make a meaningful difference in patient outcomes.”
Dr Frederic Moll, CEO and Founder of Auris Health, also remarked: “We’re thrilled to be joining Johnson & Johnson to help push the boundaries of what is possible in medical robotics and improve the lives of patients across the globe. Together, we will be able to dramatically accelerate our collective product innovation to develop new interventional solutions that redefine optimal patient outcomes. This combination is a testament to the incredible work of the Auris Health team and the innovation engine behind the Monarch Platform, which represents a huge step forward in endoluminal technology. We look forward to continuing to shape the future of intervention with the added expertise and resources of the world’s largest healthcare organization.”
Dr Moll will also be joining J&J as part of the deal, but the role he would assume was not disclosed.
Matt Fellows
Related Content
Roche’s Alecensa approved by FDA as lung cancer treatment
Roche has announced that the US Food and Drug Administration (FDA) has approved Alecensa (alectinib) …
FDA clears Oryzon’s phase 1/2 trial for lung cancer treatment
Oryzon Genomics has announced that the US Food and Drug Administration (FDA) has approved its …
Geneos Therapeutics shares data from phase 1/2 trial for cancer vaccine
Geneos Therapeutics has announced that it has published positive safety, immunogenicity and efficacy data from …
